- Report
- February 2024
- 118 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- May 2022
- 34 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- May 2022
- 134 Pages
Global
From €2290EUR$2,500USD£1,949GBP
- Report
- May 2022
- 115 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- May 2022
- 40 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- May 2022
- 37 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- March 2025
- 242 Pages
China
From €3663EUR$4,000USD£3,119GBP
- Report
- March 2025
- 80 Pages
China
From €1648EUR$1,800USD£1,403GBP
- Report
- August 2021
- 208 Pages
Global
From €2380EUR$2,598USD£2,026GBP
€3400EUR$3,712USD£2,894GBP
The Pneumonia Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat bacterial, viral, and fungal pneumonia, as well as other respiratory infections. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Commonly prescribed drugs include antibiotics, antivirals, antifungals, and corticosteroids. In addition, some drugs are used to reduce inflammation and improve breathing.
The Pneumonia Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more